Translate Bio mRNA Synthesis Patent (US12600998B2)
Summary
USPTO granted patent US12600998B2 to Translate Bio, Inc. on April 14, 2026. The patent covers methods for large-scale production of full-length messenger RNA (mRNA) substantially free of double-stranded RNA using in vitro transcription with SP6 RNA polymerase. The patent contains 19 claims and was filed as application 17502816.
What changed
USPTO granted patent US12600998B2 to Translate Bio, Inc. covering methods for large-scale production of full-length mRNA substantially free of double-stranded RNA using in vitro transcription with SP6 RNA polymerase. The patent enables mRNA therapy manufacturing without requiring chromatography steps.\n\nFor biotech companies and pharmaceutical manufacturers developing mRNA-based therapeutics, this patent may restrict competing approaches to large-scale mRNA synthesis. Other firms working in the mRNA vaccine or therapeutic space should assess whether their processes fall within the scope of these claims.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Large scale synthesis of messenger RNA
Grant US12600998B2 Kind: B2 Apr 14, 2026
Assignee
TRANSLATE BIO, INC.
Inventors
Jonathan Abysalh, Anusha Dias, Jorel E. Vargas, Dustin Cooper, Frank DeRosa
Abstract
The present invention provides, among other things, methods for large-scale production of a composition comprising full-length messenger RNA product that is substantially free of double-stranded RNA, and compositions produced using such methods and uses thereof. The present invention is based, in part, on the surprising discovery that mRNA product produced by in vitro transcription using an SP6 RNA polymerase is substantially free of double-stranded RNA. In one aspect, the present invention provides methods of generating large-scale mRNA product for mRNA therapy without need for a chromatography step.
CPC Classifications
C12N 15/1003 C12N 2330/30 C12N 9/1247 C12P 19/34 C07H 21/02 A61K 31/713
Filing Date
2021-10-15
Application No.
17502816
Claims
19
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.